This is a paid press release. Contact the press release distributor directly with any inquiries.

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

InnoCare Pharma

Fri, February 13, 2026 at 11:21 AM GMT+9 2 min read

In this article:

INCPF 0.00%

InnoCare Pharma

BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) – InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of the novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU).

Currently, patient enrollment has been completed in the Phase III registrational clinical trial of soficitinib for the treatment of moderate to severe atopic dermatitis (AD), and in the Phase II clinical trial for the treatment of vitiligo. In addition, clinical trials of soficitinib for the treatment of psoriasis and nodular prurigo are also progressing rapidly.

Soficitinib is a potent and selective TYK2 inhibitor being developed for the treatment of various T-cell related autoimmune disorders. The current indications under development are strategically positioned within the vast dermatology market. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases.

Soficitinib blocks signaling pathways such as IL-4, IL-13, IL-31, and other cytokines that drive mast cell activation and inflammation, reducing itch and wheals in CSU.

CSU is characterized by recurrent wheals and itching, with a disease course typically lasting two to five years, and in some patients, even exceeding five years. China has a large population of CSU patients, and the condition is prone to recurrent episodes. Intense nighttime itching can severely disrupt patients’ daily lives. Long-term, systematic, and standardized treatment is therefore essential for disease control.

There are approximately 50 million CSU patients worldwide, and the global CSU treatment market is expected to reach $3 billion in 2029.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “We are delighted to see the rapid progress of our five clinical trials for the TYK2 inhibitor. We hope this innovative drug will benefit more autoimmune patients as soon as possible and address their significant unmet medical needs.”

About InnoCare

InnoCare is a commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

1 DOI: 10.1007/s12325-025-03172-0 2 The Business Research Company

Terms and Privacy Policy

Privacy Dashboard

More Info